Sensei Biotherapeutics rakes in $28.5M to give cancer immunotherapies a push
Less than a month after offering a glimpse at early clinical data for its lead cancer immunotherapy at virtual ESMO, Sensei Biotherapeutics has reeled in $28.5 million to wade deeper into Phase II.
The Maryland-based biotech, formerly known as Panacea, is looking to expand Phase II trials for SNS-301, an engineered inactivated bacteriophage designed to “awaken” the immune system. “Right now we’re really focused on adding additional Phase II clinical and translational data to support SNS-301,” CEO John Celebi said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.